ERBB2 and breast carcinoma: Harris et al[6] reported that HER2 overexpression was associated with the radioresistance of breast cancer cells, while trastuzumab has been found to reverse the radioresistance,[7, 8]which suggests a potential radiosensitizing effect in the treatment of HER2+ breast tumors.